187 related articles for article (PubMed ID: 11973931)
1. [Central nervous system as a target for the new antihypertensive agents].
Nurminen ML
Duodecim; 1999; 115(20):2267-73. PubMed ID: 11973931
[No Abstract] [Full Text] [Related]
2. The renaissance of centrally acting antihypertensive drugs.
van Zwieten PA
J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
[TBL] [Abstract][Full Text] [Related]
3. [Imidazol receptor agonists--new possibilities for treating hypertension].
Nowicki M; Wiecek A; Chudek J
Postepy Hig Med Dosw; 1995; 49(5):631-43. PubMed ID: 8677226
[TBL] [Abstract][Full Text] [Related]
4. [New, modern, centrally active antihypertensive agents in the treatment of essential hypertension].
Sevcík J; Masek K
Cas Lek Cesk; 1999 Jun; 138(12):359-62. PubMed ID: 10566202
[TBL] [Abstract][Full Text] [Related]
5. Selective imidazoline receptor agonists for metabolic syndrome.
Krentz AJ; Evans AJ
Lancet; 1998 Jan; 351(9097):152-3. PubMed ID: 9449863
[No Abstract] [Full Text] [Related]
6. [New central agents in the treatment of arterial hypertension].
Robles NR
An Med Interna; 1999 Oct; 16(10):495-7. PubMed ID: 10603665
[No Abstract] [Full Text] [Related]
7. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
8. [The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
Dtsch Med Wochenschr; 1998 Aug; 123(33 Suppl):1-4. PubMed ID: 9739350
[No Abstract] [Full Text] [Related]
9. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target?
Rupp H; Jacob R
Med Hypotheses; 1995 Mar; 44(3):217-25. PubMed ID: 7609678
[TBL] [Abstract][Full Text] [Related]
10. Imidazoline receptor agonist drugs for treatment of systemic hypertension and congestive heart failure.
Palkhiwala SA; Yu A; Frishman WH
Heart Dis; 2000; 2(1):83-92. PubMed ID: 11728244
[TBL] [Abstract][Full Text] [Related]
11. Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension.
Yu A; Frishman WH
J Clin Pharmacol; 1996 Feb; 36(2):98-111. PubMed ID: 8852385
[TBL] [Abstract][Full Text] [Related]
12. [Agonists of the imidazoline receptors].
Ol'binskaia LI; Bochenkov IuV
Eksp Klin Farmakol; 1999; 62(2):68-72. PubMed ID: 10340136
[No Abstract] [Full Text] [Related]
13. [[Central agents in arterial hypertension: back to the future].
Robles NR
Nefrologia; 2000; 20(4):302-10. PubMed ID: 11039256
[No Abstract] [Full Text] [Related]
14. Pharmacology of moxonidine: an I1-imidazoline receptor agonist.
Ernsberger P
J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S27-41. PubMed ID: 11346217
[TBL] [Abstract][Full Text] [Related]
15. Centrally acting imidazoline I1-receptor agonists: do they have a place in the management of hypertension?
van Zwieten PA
Am J Cardiovasc Drugs; 2001; 1(5):321-6. PubMed ID: 14728014
[TBL] [Abstract][Full Text] [Related]
16. [Centrally acting sympathetic inhibitors for therapy of patients with hypertension].
Kawasaki H
Nihon Rinsho; 1997 Aug; 55(8):2081-5. PubMed ID: 9284427
[TBL] [Abstract][Full Text] [Related]
17. [Imidazoline receptor agonists in the practical treatment of hypertension].
Ol'binskaia LI; Bochenkov IuV; Alekseeva IL
Ter Arkh; 1998; 70(2):86-8. PubMed ID: 9551585
[No Abstract] [Full Text] [Related]
18. An unexpected central hypertensive effect of the new imidazoline compound benazoline.
Bruban V; Feldman J; Dontenwill M; Greney H; Brasili L; Giannella M; Pigini M; Bousquet P
Ann N Y Acad Sci; 1999 Jun; 881():102-5. PubMed ID: 10415903
[No Abstract] [Full Text] [Related]
19. [New trends in the treatment of arterial hypertension: identification of the I1 receptor and the pharmacology of imidazoline].
Pavlović P
Vojnosanit Pregl; 1998; 55(3):305-10. PubMed ID: 9720446
[No Abstract] [Full Text] [Related]
20. Metabolic effects of moxonidine and other centrally acting antihypertensives.
Schachter M
Diabetes Obes Metab; 1999 Nov; 1(6):317-22. PubMed ID: 11225647
[No Abstract] [Full Text] [Related]
[Next] [New Search]
